The specific objectives of the Pathology and Tissue Procurement Core are to: Provide a centralized resource dedicated to procurement and processing of tumor tissue for translational research from nearly every patient with newly diagnosed or relapsed primary central nervous system tumors receiving care at the Mayo Clinic, Rochester, MN. - Coordinate acquisition and timely distribution of brain tumor tissue in excess of clinical diagnosis, ensuring appropriate diagnosis and quality of tissue. A portion of fresh tumoral brain tissue and normal tissue (when available) from each patient will be obtained fresh, processed for culture/xenografting and/or stored frozen to provide investigators with DNA and RNA. The remainder of the tissue will be available in paraffin blocks stored at the Mayo Clinic Tissue Registry. Provide a comprehensive histologic characterization of all tissue samples used in the individual SPORE Projects, including specimens from patients and experimental tumors in animals, as well as provide expertise in the interpretation of studies performed on paraffin embedded and/or frozen tissue sections. - Offer comprehensive services, including immunohistochemical characterization of biomarkers, tissue microarray design and construction, and DNA or RNA extraction. - Maintain and enhance a repository of tumor tissue and matched blood specimens in conjunction with the Clinical Research Core. The Core will interface with and be electronically integrated with the Clinical Research and the Biostatistics Cores to provide investigators with clinically annotated tissues. The collection, banking, and use of tissue will be performed with appropriate patient consent and institutional approval. - Promote and facilitate sharing of tissue resources with other Brain Tumor SPOREs through collaborative scientific projects of mutual interest.

Public Health Relevance

Compared to other more common cancers malignant gliomas are responsible for a disproportionate amount of morbidity and mortality because of their disabling impact on cognition, memory, language, mobility and adaptive skills. Well characterized, pathologically and clinically annotated tumor tissues from patients with malignant gliomas are a critical and precious resource on translating the basic molecular and biological understanding of gliomas into improved treatments for patients.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Oi, N; Yuan, J; Malakhova, M et al. (2015) Resveratrol induces apoptosis by directly targeting Ras-GTPase-activating protein SH3 domain-binding protein 1. Oncogene 34:2660-71
Choi, Jae Won; Schroeder, Mark A; Sarkaria, Jann N et al. (2014) Cyclophilin B supports Myc and mutant p53-dependent survival of glioblastoma multiforme cells. Cancer Res 74:484-96
Bradley, Barrie S; Loftus, Joseph C; Mielke, Clinton J et al. (2014) Differential expression of microRNAs as predictors of glioblastoma phenotypes. BMC Bioinformatics 15:21
Walsh, Kyle M; Codd, Veryan; Smirnov, Ivan V et al. (2014) Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet 46:731-5
Bell, Michael P; Renner, Danielle N; Johnson, Aaron J et al. (2014) An elite controller of picornavirus infection targets an epitope that is resistant to immune escape. PLoS One 9:e94332
Catteau, Aurélie; Girardi, Hélène; Monville, Florence et al. (2014) A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma. Acta Neuropathol Commun 2:58
Johnson, Holly L; Jin, Fang; Pirko, Istvan et al. (2014) Theiler's murine encephalomyelitis virus as an experimental model system to study the mechanism of blood-brain barrier disruption. J Neurovirol 20:107-12
Gupta, Shiv K; Mladek, Ann C; Carlson, Brett L et al. (2014) Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts. Clin Cancer Res 20:3730-41
Assefnia, Shahin; Dakshanamurthy, Sivanesan; Guidry Auvil, Jaime M et al. (2014) Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies. Oncotarget 5:1458-74
Wang, Enfeng; Zhang, Chunyang; Polavaram, Navatha et al. (2014) The role of factor inhibiting HIF (FIH-1) in inhibiting HIF-1 transcriptional activity in glioblastoma multiforme. PLoS One 9:e86102

Showing the most recent 10 out of 103 publications